Daewoong Pharmaceutical Announces Us Fda Clearance Of Ind Application For Dwp213388 First In Class Irreversible Oral Dual Acting Inhibitor For Autoimmune Diseases

Daewoong Pharmaceutical Announces Us Fda Clearance Of Ind Application For Dwp213388 First In Class Irreversible Oral Dual Acting Inhibitor For Autoimmune Diseases

By, Admin 16 August 2022

Dwp213388 Is A First-In-Class Dual-Target Inhibitor That Simultaneously Inhibits Pathogenic T Cells And B Cells Across A Range Of Autoimmune Disease Daewoong Pharmaceutical Co., Ltd. Is A Publicly Traded South Korean Pharmaceutical Company That Develops, Manufactures, And Commercializes Pharmaceuticals Globally Today Announced That The U.S. Food And Drug Administration (Fda) Has Cleared An Investigational New Drug (Ind) Application To Initiate A Phase 1 Clinical Trial Of Dwp213388, A New Drug Candidate Being Developed For Autoimmune Diseases. Daewoong Pharmaceutical Ceo Seng-Ho Jeon Said, "Daewoong Pharmaceutical Plans To Lead The Development Of Various Global New Drugs Such As Dwp213388 In Collaboration With Global Licensees For Patients With Autoimmune Diseases" And He Added That "We Will Contribute To Improving The Quality Of Life Of Many Patients Around The World Who Are Suffering From Lack Of A Cure."The Planned Phase 1 Clinical Trial Is A Double-Blind, Randomized, Placebo-Controlled, A Single And Multiple Doses Escalation Study In 80 Healthy Subjects. It Will Assess The Safety, Pharmacokinetics And Pharmacodynamic Responses Of Dwp213388 As A First-In-Class Strategy To Treat Autoimmune. The Trial Is Projected To Initiate In 2H 2022 In The Usa.Unlike Current Treatments, Which Are Generally Limited To Inhibiting Only B Cells Or T Cells, Dwp213388 Is A Dual-Target Inhibitor That Simultaneously Inhibits B Cells And T Cells, Thus Has Higher Efficacy Potential Than Conventional Single-Action Treatments. It Selectively Inhibits Both Bruton'S Tyrosine Kinase (Btk) And Interleukin-2-Inducible T-Cell Kinase (Itk). Daewoong Has Demonstrated That This Dual Activity Was Safe And Effective At Preventing Or Reducing Autoimmune Pathology In A Number Of Preclinical Models.According To Research And Markets, A Global Market Research Institute, The Global Autoimmune Disease Treatment Market Is Growing At An Average Annual Rate Of 4.2% And Is Expected To Reach $153 Billion (About 200 Trillion Krw) By 2025.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!